Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft

Summary

This is a multicenter, open-label phase II study, assessing the efficacy of elotuzumab in elderly patients with multiple myeloma undergoing peripheral stem cell autologous graft

Timeline

Start

2018-02-20

Primary completion

2019-01-15

Completion

2019-01-15

Outcome

Outcome not reported

Stopped: “Investigator decision in accordance with the promotor”

Drugs

Indications